November 3rd, 2026 - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that VIVALDI, a Phase Ib pilot study sponsored by CETLAM — Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplásicas, has been authorized in Spain. The study will evaluate iadademstat in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia (ND-AML) belongin

GLORIA Study Team Receives the 2026 German University Medicine Prize for Its Glioblastoma Research with CXCL12 Inhibitor NOX-A12 Researchers from six German university medical centers have received the 2026 German University Medicine Prize for their work in the GLORIA study GLORIA, TME Pharma’s Phase 1/2 study, evaluates NOX-A12 in combination with radiotherapy in newly diagnosed glioblastoma patients who are resistant to chemotherapy. In an expansion cohort, NOX-A12 and radiotherapy were also c

Oct. 30, 2026 -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been dosed in the Phase 1 trial of ICP-B161, a bispecific antibody targeting TL1A and IL-23p19, for the potential treatment of autoimmune diseases, including inflammatory bowel disease (IBD). With its novel molecular design, ICP-B161 delivers an extended half-life, which allows for less frequent d

- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia - Oct. 30, 2026 -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib) has been recognized as the Best Product for Rare/Orphan Diseases of 2026 by The Galien Foundation. The Galien Foundation fosters, recognizes, and r

INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgery VOCERYQ™ is a plasmid DNA-based immunotherapy that targets the root cause of RRP: HPV-6 and HPV-11 INOVIO expects to make VOCERYQ available to order and ship in approximately 60 days, with full commercial launch in the first quarter of 2027 VOCERYQ represents the first U.S. FDA approved DNA medicine, validating INOVIO's novel platform

The Phase III AIRWARD™ trial was published today on ClinicalTrials.gov (NCT07907991).1 AIRWARD will evaluate the efficacy and safety of verducatib, an investigational oral therapy for COPD.1 The Phase III trial will enroll adults with symptomatic COPD who continue to experience exacerbations and have blood eosinophil counts below 300 cells/µL.1 Boehringer Ingelheim today announced the registration of the Phase III AIRWARD™ trial evaluating its investigational oral therapy verducatib as a treatm

In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs. 1.8% with Ozempic 2 mg at 80 weeks Participants taking retatrutide lost an average of 44 lbs to 47 lbs (20% to 21%) vs. 21 lbs (9%) with Ozempic 2 mg at 80 weeks TRANSCEND-T2D-2 marks the sixth Phase 3 trial in which retatrutide has delivered powerful efficacy, reinforcing its potential to transform cardiometabolic care Oct 28, 2026 -- Eli Lilly and Company (NYSE: LLY), the maker of Mounjaro (tirzepatide) and Foun

The US Food and Drug Administration (FDA) has granted orphan drug designation to Octant’s OCT-980, an investigational oral small molecule, to treat retinitis pigmentosa (RP). The regulatory status specifically includes rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), the indication for which the candidate is presently being evaluated. Orphan status is granted to support the development of therapies for rare diseases and conditions. This designation offers financial and re

Nxera has exercised its option to license lucerastat for Japan, South Korea, Taiwan and selected other Asia Pacific markets (excluding China), paying Idorsia CHF 7 million upfront and contributing to the global Phase 3 program. Lucerastat is an investigational oral therapy for Fabry disease with more than 400 patient-years of clinical experience, adding a late-stage rare disease asset to Nxera's portfolio in Japan and Asia Pacific. Idorsia today initiated FAB-KLEAR, a pivotal Phase 3 study, as

Company also announces appointment of Stanford mitochondrial disease expert to its Scientific and Clinical Advisory Board and launch of two new pipeline programs Adjuvia Therapeutics, a biotechnology company developing novel therapeutics to treat mitochondrial dysfunction and disease, today announced that the first participant has been dosed in its Phase 1 clinical trial of ATI-105, its lead investigational therapeutic candidate for Friedreich’s ataxia (FA). The milestone follows the U.S. Food